Status:
UNKNOWN
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Lead Sponsor:
University of Leicester
Conditions:
Peripheral Arterial Disease
Eligibility:
All Genders
18+ years
Brief Summary
Peripheral arterial disease (PAD) is a condition where the blood vessels in the legs get blocked. It affects one out of every five adults over the age of 65. As it is the main cause of amputations, th...
Detailed Description
Patients with peripheral arterial disease, a condition whereby arteries in the legs become narrow or blocked, are not only at a higher risk of limb loss but also of suffering heart attacks and strokes...
Eligibility Criteria
Inclusion
- Patients over the age of 18 years.
- Patients with severely symptomatic aorto-iliac and infra-inguinal peripheral arterial disease.
- Patients with the ability to provide written informed consent.
- Patients on antiplatelet therapy
Exclusion
- Patients under the age of 18 years.
- Patients unable or unwilling to provide written informed consent.
- Patients with acute limb ischaemia of the lower limb.
- Patients with aneurysmal disease of the arteries of the lower limb.
- Patients with severe diabetic foot sepsis.
- Patients with a known history of clotting disorders
- Patients with inherited bleeding disorders
Key Trial Info
Start Date :
September 29 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06047002
Start Date
September 29 2022
End Date
December 31 2024
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Leicester
Leicester, United Kingdom, LE3 9QP